PHILADELPHIA, PA — Cabaletta Bio Inc. (Nasdaq: CABA) has granted stock options covering 240,200 shares to four newly hired employees as part of its recruitment compensation, giving the Philadelphia biotechnology company’s new staff an equity stake tied to its future stock performance.
The options carry an exercise price of $1.43 per share, equal to Cabaletta’s Nasdaq closing share price on Nov. 2, 2026, according to the company.
The awards were issued to four non-executive employees as incentives to join Cabaletta and were approved under Nasdaq Listing Rule 5635(c)(4), which permits qualifying equity grants to new employees as an inducement to employment.
At the exercise price, the aggregate options represent approximately $343,486 in potential proceeds to Cabaletta if fully exercised. The options have a 10-year term.
The awards vest over four years, with 25% becoming exercisable on the first anniversary of each employee’s employment start date. The remaining 75% will vest in 12 equal quarterly installments over the following three years.
The grants are governed by Cabaletta’s 2025 Inducement Plan and the applicable stock option agreements.
Cabaletta is developing cell therapies for autoimmune diseases, with its lead investigational treatment, rese-cel, advancing through the company’s RESET clinical development program.
Rese-cel is a CD19-directed chimeric antigen receptor T-cell therapy incorporating a 4-1BB signaling domain. The program spans several autoimmune disease areas, including rheumatology, neurology and dermatology.
Cabaletta maintains its headquarters and laboratories in Philadelphia, where it is advancing its clinical development operations.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.